Puma Biotechnology (NASDAQ:PBYI – Get Free Report) and Shattuck Labs (NASDAQ:STTK – Get Free Report) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, dividends, earnings, valuation, institutional ownership, profitability and analyst recommendations.
Analyst Ratings
This is a breakdown of recent recommendations and price targets for Puma Biotechnology and Shattuck Labs, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Puma Biotechnology | 0 | 0 | 1 | 0 | 3.00 |
| Shattuck Labs | 0 | 0 | 2 | 0 | 3.00 |
Puma Biotechnology presently has a consensus price target of $7.00, indicating a potential upside of 41.41%. Shattuck Labs has a consensus price target of $20.00, indicating a potential upside of 105.13%. Given Shattuck Labs’ higher probable upside, analysts plainly believe Shattuck Labs is more favorable than Puma Biotechnology.
Profitability
| Net Margins | Return on Equity | Return on Assets | |
| Puma Biotechnology | 9.16% | 58.21% | 10.40% |
| Shattuck Labs | -5,268.44% | -63.08% | -56.05% |
Risk & Volatility
Puma Biotechnology has a beta of 1.28, suggesting that its stock price is 28% more volatile than the S&P 500. Comparatively, Shattuck Labs has a beta of 2.11, suggesting that its stock price is 111% more volatile than the S&P 500.
Valuation & Earnings
This table compares Puma Biotechnology and Shattuck Labs’ top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Puma Biotechnology | $235.60 million | 1.01 | $21.59 million | $0.46 | 10.70 |
| Shattuck Labs | $1.66 million | 274.53 | -$87.30 million | ($2.05) | -4.68 |
Puma Biotechnology has higher revenue and earnings than Shattuck Labs. Shattuck Labs is trading at a lower price-to-earnings ratio than Puma Biotechnology, indicating that it is currently the more affordable of the two stocks.
Insider & Institutional Ownership
61.3% of Puma Biotechnology shares are owned by institutional investors. Comparatively, 58.7% of Shattuck Labs shares are owned by institutional investors. 22.7% of Puma Biotechnology shares are owned by company insiders. Comparatively, 9.9% of Shattuck Labs shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Summary
Puma Biotechnology beats Shattuck Labs on 8 of the 12 factors compared between the two stocks.
About Puma Biotechnology
Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine. It also develops alisertib, a small molecule inhibitor of aurora kinase A for the treatment of hormone receptor positive breast cancer, triple negative breast cancer, small cell lung cancer, and head and neck cancer. The company sells its products through specialty pharmacy and distributor networks. It has license agreements with Pfizer Inc. for the development, manufacture, and commercialization of neratinib (oral), neratinib (intravenous), PB357, and related compounds; and Takeda Pharmaceutical Company Limited for the research, development, and commercialization of alisertib, as well as sub-license agreements with Specialised Therapeutics Asia Pte Ltd., Medison Pharma Ltd., Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. The company was founded in 2010 and is headquartered in Los Angeles, California.
About Shattuck Labs
Shattuck Labs, Inc., a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers. Shattuck Labs, Inc. was incorporated in 2016 and is headquartered in Austin, Texas.
Receive News & Ratings for Puma Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Puma Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.
